| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6077843 | JANSSEN PHARMS | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
May, 2017
(6 years ago) | |
|
US6077843 (Pediatric) | JANSSEN PHARMS | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
Nov, 2017
(6 years ago) | |
| US10143693 | JANSSEN PHARMS | Dosing regimen for missed doses for long-acting injectable paliperidone esters |
Apr, 2036
(11 years from now) | |
Invega Trinza is owned by Janssen Pharms.
Invega Trinza contains Paliperidone Palmitate.
Invega Trinza has a total of 3 drug patents out of which 2 drug patents have expired.
Expired drug patents of Invega Trinza are:
- US6077843
- US6077843*PED
Invega Trinza was authorised for market use on 30 August, 2021.
Invega Trinza is available in suspension, extended release;intramuscular dosage forms.
Invega Trinza can be used as treatment of schizophrenia, reinitiation of schizophrenia treatment following a missed dose more than 9 months ago.
The generics of Invega Trinza are possible to be released after 05 April, 2036.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Strength(NS) | Aug 30, 2024 |
| New Product(NP) | May 18, 2018 |
Drugs and Companies using PALIPERIDONE PALMITATE ingredient
Market Authorisation Date: 30 August, 2021
Treatment: Treatment of schizophrenia; Reinitiation of schizophrenia treatment following a missed dose more than 9 months ago
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
INVEGA TRINZA family patents
